Jinzi Wu
Algemeen Directeur bij ASCLETIS PHARMA INC.
Vermogen: 88 M $ op 31-05-2024
Actieve functies van Jinzi Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ASCLETIS PHARMA INC. | Algemeen Directeur | - | - |
| Voorzitter | - | - | |
| Oprichter | - | - | |
| Ascletis Pharma China Co., Ltd. | Directeur/Bestuurslid | 01-03-2018 | - |
| Gannex LLC | Corporate Officer/Principal | 01-10-2020 | - |
| Gannex Pharma Co Ltd. | Algemeen Directeur | 01-01-2019 | - |
| Oprichter | 01-01-2019 | - | |
| Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | Directeur/Bestuurslid | 01-04-2019 | - |
| Ascletis Xinnuo Medicine Co., Ltd | Directeur/Bestuurslid | 01-07-2018 | - |
| Algemeen Directeur | 01-07-2018 | - | |
| Ascletis BioScience Co., Ltd. | Directeur/Bestuurslid | 01-04-2013 | - |
| Algemeen Directeur | 01-04-2013 | - | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Algemeen Directeur | - | - |
| Voorzitter | 07-04-2011 | - | |
| Oprichter | 07-04-2011 | - | |
| President | 07-04-2011 | - | |
| The BayHelix Group | Corporate Officer/Principal | 08-04-2011 | - |
Loopbaan van Jinzi Wu
Eerdere bekende functies van Jinzi Wu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Jinzi Wu
| Nanjing University | Graduate Degree |
| University of Arizona | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 10 |
| China | 8 |
| Canada | 2 |
Operationeel
| Corporate Officer/Principal | 10 |
| Director/Board Member | 5 |
| Chief Executive Officer | 5 |
Sectoraal
| Health Technology | 10 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| GSK PLC | Health Technology |
| NOVARTIS AG | Health Technology |
| SANOFI INDIA LIMITED | Health Technology |
| ASCLETIS PHARMA INC. | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 13 |
|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
| Ascletis BioScience Co., Ltd. | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
| The BayHelix Group | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| Ascletis Xinnuo Medicine Co., Ltd | |
| Ascletis Pharma China Co., Ltd. | |
| Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | |
| Gannex Pharma Co Ltd. | |
| Gannex LLC | |
PhageTech, Inc.
 PhageTech, Inc. Miscellaneous Commercial ServicesCommercial Services PhageTech, Inc. provides medical services. The firm develops bacteriophage sensors related tests for detecting analytes in urine, blood, and other body fluids. Its technology is used for advanced diagnostics, such as early stage cancer detection, drug dosage monitoring, and time sensitive diseases and conditions. The company was founded by Richard W. Henson, Gregory Weiss, and Reginald Penner in 2014 and is headquartered in Irvine, CA. | Commercial Services |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Ascletis Pharmaceuticals Co., Ltd. |
